Document:

Amended and Restated Investor Rights Agreement

 Exhibit 4.2 
 SECOND OMNIBUS AMENDMENT 
 This Second Omnibus Amendment, dated as of December 19, 2007 (this
“Omnibus Amendment”) amends (i) that certain Amended and Restated Investor Rights Agreement, dated October 4, 2004, by and among Bayhill Therapeutics, Inc., a Delaware corporation (the “Company”) and the
Investors (as defined therein), as amended by the Omnibus Amendment, dated as of February 8, 2006, by and among the Company, the Investors and certain other parties (the “First Omnibus Amendment”) (the “IRA”),
(ii) that certain Amended and Restated Right of First Refusal and Co-Sale Agreement, dated October 4, 2004, by and among the Company, the Investors (as defined therein) and the Major Common Holders (as defined therein), as amended by the
First Omnibus Amendment (the “ROFR Agreement”) and (iii) that certain Amended and Restated Voting Agreement, dated October 4, 2004, by and among the Company, the Investors (as defined therein) and the Major Common Holders
(as defined therein), as amended by the First Omnibus Amendment (the “Voting Agreement”). 
 RECITALS

 WHEREAS: The Company, the Investors and the Major Common Holders wish to amend the IRA, the ROFR Agreement and the
Voting Agreement to permit certain additional purchasers of the Company’s Series B Preferred Stock pursuant to that certain Series B Preferred Stock Purchase Agreement, dated as of the date hereof, by and among the Company and the Purchasers
(as defined therein), to become parties to the IRA, the ROFR Agreement and the Voting Agreement. 
 WHEREAS: Section 3.4
of the IRA provides that the IRA may be amended with the written consent of the Company and holders of a majority of the outstanding Registrable Securities (as defined therein) (the “IRA Amendment Threshold”); 
 WHEREAS: Section 4.2 of the ROFR Agreement provides that the ROFR Agreement may be amended with the written consent of the Company,
holders of a majority of the Common Stock (as defined therein) issued or issuable upon conversion of the Preferred Stock (as defined therein) and holders of a majority of the Major Common Holders’ Shares (as defined therein) (the “ROFR
Agreement Amendment Threshold”); 
 WHEREAS: Section 4.2 of the Voting Agreement provides that the Voting
Agreement may be amended with the written consent of the Company, the Major Common Holders (as defined therein) holding a majority of shares of Common Stock (as defined therein) held by such Major Common Holders, and Investors holding a majority of
the outstanding shares of Preferred Stock held by all Investors (the “Voting Agreement Amendment Threshold”); and 
 WHEREAS: The undersigned meet each of the IRA Amendment Threshold, the ROFR Agreement Amendment Threshold and the Voting Agreement Amendment Threshold. 

 NOW, THEREFORE: In consideration of the mutual promises and covenants set forth herein, and other
consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows: 
 1. IRA Amendment.
Section 3.14 of the IRA is hereby deleted in its entirety and replaced with the following: 
 “Additional
Parties. Persons who become ‘Purchasers’ of the Company’s Series B Preferred Stock after the effective date of this Agreement pursuant to and in accordance with (a) the Purchase Agreement, (b) the
Series B Preferred Stock Purchase Agreement, dated as of February 8, 2006 by and among the Company and the Purchasers (as defined therein), or (c) the Series B Preferred Stock Purchase Agreement, dated as of December 19,
2007 by and among the Company and the Purchasers (as defined therein), and who execute signature pages to this Agreement or any amendment of this Agreement shall become parties hereto, and no consent or waiver of any other party hereto, other than
the Company, shall be required to add any such additional party.” 
 2. ROFR Amendment. Section 4.8 of the ROFR Agreement is
hereby deleted in its entirety and replaced with the following: 
 “Additional Investors. Notwithstanding
anything to the contrary contained herein, if the Company shall issue additional shares of Series B Preferred Stock, pursuant to (a) the Purchase Agreement, (b) the Series B Preferred Stock Purchase Agreement, dated as of
February 8, 2006, by and among the Company and the Purchasers (as defined therein), or (c) the Series B Preferred Stock Purchase Agreement, dated as of December 19, 2007, by and among the Company and the Purchasers (as defined
therein), any purchaser of such shares shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement or any amendment of this Agreement and shall be deemed an
‘Investor’ hereunder.” 
 3. Voting Agreement Amendment. Section 4.8 of the
Voting Agreement is hereby deleted in its entirety and replaced with the following: 
 “Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of Series B Preferred Stock, pursuant to (a) the Purchase Agreement, (b) the Series B Preferred Stock Purchase
Agreement, dated as of February 8, 2006, by and among the Company and the Purchasers (as defined therein), or (c) the Series B Preferred Stock Purchase Agreement, dated as of December 19, 2007, by and among the Company and the
Purchasers (as defined therein), any purchaser of such shares shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement or any amendment of this Agreement and shall be deemed an
‘Investor’ hereunder.” 
 4. Merger. Except as expressly amended above, the IRA, the ROFR Agreement and the
Voting Agreement shall remain in full force and effect. 
 5. Counterparts. This Second Omnibus Amendment may be executed in any
number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

 6. Governing Law. This Second Omnibus Amendment shall be construed and interpreted in accordance
with and be governed by the laws of the State of California without giving effect to any conflict of laws principles that would result in the application of the laws of any state other than the State of California. 
 [Signature Pages Follow] 

 IN WITNESS WHEREOF, the parties hereto have executed this Second Omnibus Amendment effective as of the
day and year first above written. 
  

									
		 		 	BAYHILL THERAPEUTICS, INC.
		 		 	a Delaware corporation
					
		 		 		 	By:	 	/s/ Mark W. Schwartz
		 		 		 	Name:	 	Mark W. Schwartz
		 		 		 	Title:	 	President and Chief Executive Officer
			
		 		 	MAJOR COMMON HOLDERS:
			
	LAWRENCE STEINMAN, MD	 		 	WILLIAM H. ROBINSON, MD, PHD
					
	By:	 	/s/ Lawrence Steinman, MD	 		 	By:	 	/s/ William H. Robinson, MD, PhD
			
	PAUL J. UTZ, MD	 		 	HIDEKI GARREN, MD, PHD
					
	By:	 	Paul J. Utz, MD	 		 	By:	 	Hideki Garren, MD, PhD
			
	MARTIN H. GOLDSTEIN	 		 	
				
	By:	 	 	 		 	

					
	PREFERRED STOCKHOLDERS:
	
	LATTERELL VENTURE PARTNERS, L.P.
		
	By:	 	Latterell Capital Management, L.L.C., its general partner
			
		 	By:	 	/s/ Patrick F. Latterell
		 		 	Patrick F. Latterell, Managing Member
	
	LATTERELL VENTURE PARTNERS II, L.P.
		
	By:	 	Latterell Capital Management II, L.L.C., its general partner
			
		 	By:	 	/s/ Patrick F. Latterell
		 		 	Patrick F. Latterell, Managing Member
	
	PREFERRED STOCKHOLDERS:
	
	U.S. Venture Partners VIII, L.P.
	USVP VIII Affiliates Fund, L.P.
	USVP Entrepreneur Partners VIII-A, L.P.
	USVP Entrepreneur Partners VIII-B, L.P.
	By Presidio Management Group VIII, L.L.C.
	The General Partner of Each
		
	By:	 	/s/ Michael P. Maher
		 	Michael P. Maher, Attorney-In-Fact
	
	Address:
	2735 Sand Hill Road
	Menlo Park CA 94025
	Facsimile No.: (650) 854-3018
	Attn: Chief Financial Officer
	Email: deals@usvp.com

			
	PREFERRED STOCKHOLDERS:
	
	Morgenthaler Partners VII, L.P.
		
	By:	 	Morgenthaler Management Partners VII, LLC,
		 	Its Managing Partner

			
		
	By:	 	/s/ James Broderick
	Name:	 	James Broderick
	Title:	 	Member

			
	
	PREFERRED STOCKHOLDERS:
	
	VERTICAL FUND I, L.P.
		
	By:	 	The Vertical Group, L.P., General Partner
		
	By:	 	/s/ Stephen D. Baksa
		 	Stephen D. Baksa, General Partner
	
	VERTICAL FUND II, L.P.
		
	By:	 	The Vertical Group, L.P., General Partner
		
	By:	 	/s/ Stephen D. Baksa
		 	Stephen D. Baksa, General Partner

			
	PREFERRED STOCKHOLDERS:
	
	CMEA VENTURES LIFE SCIENCES 2000, L.P.
		
	By:	 	/s/ David J. Collier, MD
	Name:	 	David J. Collier, MD
	Title:	 	General Partner, CMEA Ventures LS Management 2000, L.P., the General Partner of CMEA Ventures Life Sciences 2000,
L.P.
	
	CMEA VENTURES LIFE SCIENCES 2000, CIVIL LAW PARTNERSHIP
		
	By:	 	/s/ David J. Collier, MD
	Name:	 	David J. Collier, MD
	Title:	 	General Partner, CMEA Ventures LS Management 2000, L.P., the Managing Partner of CMEA Ventures Life Sciences 2000, Civil Law Partnership
	
	PREFERRED STOCKHOLDERS:
	
	THE MENDELSON FAMILY TRUST
		
	By:	 	/s/ Alan C. Mendelson
	Name:	 	Alan C. Mendelson
	
	VP COMPANY INVESTMENTS 2008, LLC
		
	By:	 	/s/ Alan C. Mendelson
	Name:	 	Alan C. Mendelson
	Title:	 	Managing Member

					
	PREFERRED STOCKHOLDERS:
	
	LILLY VENTURES
	Eli Lilly and Company
		
	By:	 	/s/ Darren J. Carroll
	Name:	 	Darren J. Carroll
	Title:	 	Executive Director

					
	
	PREFERRED STOCKHOLDERS:
	
	DE NOVO VENTURES II, L.P.
		
	By:	 	De Novo Management II, L.L.C., Its General Partner
			
		 	By:	 	/s/ Cathy Minshall
		 		 	Cathy Minshall, Chief Financial Officer
	
	PREFERRED STOCKHOLDERS:
	
	A. M. PAPPAS LIFE SCIENCE VENTURES II, LP
		
	By:	 	AMP&A Management II, LLC, its General Partner
			
		 	By:	 	/s/ Ford S. Worthy
		 		 	Ford S. Worthy, Partner

					
	PREFERRED STOCKHOLDERS:
	
	MONTREUX EQUITY PARTNERS II SBIC, L.P.
		
	By:	 	Montreux Equity Management II, LLC,
		 	its General Partner
			
		 	By:	 	/s/ Daniel K. Turner, III
		 		 	Daniel K. Turner, III
		 		 	Managing Member
	
	MONTREUX EQUITY PARTNERS III SBIC, L.P.
		
	By:	 	Montreux Equity Management III, LLC,
		 	its General Partner
			
		 	By:	 	/s/ Daniel K. Turner, III
		 		 	Daniel K. Turner, III
		 		 	Managing Member

					
	
	PREFERRED STOCKHOLDERS:
	
	BOSTON LIFE SCIENCE VENTURE CORPORATION
		
	By:	 	Peter T. K. Wu
	Name:	 	Peter T. K. Wu
	Title:	 	Chairman

			
	PREFERRED STOCKHOLDERS:
	
	GRAND CATHAY VENTURE CAPITAL II CO., LTD.
		
	By:	 	/s/ Edward Chang
	Name:	 	Edward Chang
	Title:	 	President
	
	GRAND CATHAY VENTURE CAPITAL III CO., LTD.
		
	By:	 	/s/ Edward Chang
	Name:	 	Edward Chang
	Title:	 	President
	
	PRUDENCE VENTURE INVESTMENT CORP.
		
	By:	 	/s/ Jessica Wu
	Name:	 	Jessica Wu
	Title:	 	President

			
	PREFERRED STOCKHOLDERS:
	
	PAC-LINK BIO VENTURE CAPITAL INVESTMENT CORP.
		
	By:	 	/s/ Hsu Shan-Ko
	Name:	 	Hsu Shan-Ko
	Title:	 	Chairman
	
	PREFERRED STOCKHOLDERS:
	
	PHARMABIO DEVELOPMENT, INC.
		
	By:	 	/s/ Kerry E. Zook
	Name:	 	Kerry E. Zook
	Title:	 	VP & General Counsel

			
	KOENIG FAMILY REVOCABLE TRUST DATED JUNE 1, 2004
		
	By:	 	/s/ Robert A. King
	Name:	 	Robert A. King
	Title:	 	Trustee

			
	
	EMINENT VENTURE CAPITAL CORPORATION
		
	By:	 	/s/ Jyan-Ming Yang
		 	Jyan-Ming Yang
		 	President

 OMNIBUS AMENDMENT 
 This Omnibus Amendment, dated as of February 8, 2006 (this “Omnibus Amendment”) amends (i) that certain Amended and Restated Investor Rights Agreement, dated October 4, 2004, by and
among Bayhill Therapeutics, Inc., a Delaware corporation (the “Company”) and the Investors (as defined therein) (“the “IRA”), (ii) that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated October 4, 2004, by and among the Company, the Investors (as defined therein) and the Major Common Holders (as defined therein) (the “ROFR Agreement”) and (iii) that certain Amended and Restated Voting
Agreement, dated October 4, 2004, by and among the Company, the Investors (as defined therein) and the Major Common Holders (as defined therein) (the “Voting Agreement”). 
 RECITALS 
 WHEREAS: The Company, the Investors and the
Major Common Holders wish to amend the IRA, the ROFR Agreement and the Voting Agreement to permit certain additional purchasers of the Company’s Series B Preferred Stock pursuant to that certain Series B Preferred Stock Purchase Agreement,
dated as of the date hereof, by and among the Company and the Purchasers (as defined therein), to become parties to the IRA, the ROFR Agreement and the Voting Agreement. 
 WHEREAS: Section 3.4 of the IRA provides that the IRA may be amended with the written consent of the Company and holders of a majority of the outstanding Registrable Securities (as defined therein)
(the “IRA Amendment Threshold”); 
 WHEREAS: Section 4.2 of the ROFR Agreement provides that the ROFR
Agreement may be amended with the written consent of the Company, holders of a majority of the Common Stock (as defined therein) issued or issuable upon conversion of the Preferred Stock (as defined therein) and holders of a majority of the Major
Common Holders’ Shares (as defined therein) (the “ROFR Agreement Amendment Threshold”); 
 WHEREAS:
Section 4.2 of the Voting Agreement provides that the Voting Agreement may be amended with the written consent of the Company, the Major Common Holders holding a majority of shares of Common Stock held by such Major Common Holders, and
Investors holding a majority of the outstanding shares of Preferred Stock held by all Investors (the “Voting Agreement Amendment Threshold”); and 
 WHEREAS: The undersigned meet each of the IRA Amendment Threshold, the ROFR Agreement Amendment Threshold and the Voting Agreement Amendment Threshold. 

 NOW, THEREFORE: In consideration of the mutual promises and covenants set forth herein, and other
consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows: 
 1. IRA Amendment.
Section 3.14 of the IRA is hereby deleted in its entirety and replaced with the following: 
 “Additional
Parties. Persons who become ‘Purchasers’ of the Company’s Series B Preferred Stock after the effective date of this Agreement pursuant to and in accordance with the Purchase Agreement or the Series B Preferred
Stock Purchase Agreement, dated as of February 8, 2006 by and among the Company and the Purchasers (as defined therein), and who execute signature pages to this Agreement or any amendment of this Agreement shall become parties hereto, and no
consent or waiver of any other party hereto, other than the Company, shall be required to add any such additional party.” 
 2. ROFR
Amendment. Section 4.8 of the ROFR Agreement is hereby deleted in its entirety and replaced with the following: 
 “Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of Series B Preferred Stock, pursuant to the Purchase Agreement or the Series B Preferred
Stock Purchase Agreement, dated as of February 8, 2006, by and among the Company and the Purchasers (as defined therein), any purchaser of such shares shall become a party to this Agreement by executing and delivering an additional counterpart
signature page to this Agreement or any amendment of this Agreement and shall be deemed an ‘Investor’ hereunder.” 
 3. Voting Agreement Amendment. Section 4.8 of the Voting Agreement is hereby deleted in its entirety and replaced with the following: 
 “Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company shall issue additional
shares of Series B Preferred Stock, pursuant to the Purchase Agreement or the Series B Preferred Stock Purchase Agreement, dated as of February 8, 2006, by and among the Company and the Purchasers (as defined therein), any purchaser of
such shares shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement or any amendment of this Agreement and shall be deemed an ‘Investor’ hereunder.”

 4. Merger. Except as expressly amended above, the IRA, the ROFR Agreement and the Voting Agreement shall remain in full force and
effect. 
 5. Counterparts. This Omnibus Amendment may be executed in any number of counterparts, each of which shall be enforceable
against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 
 6. Governing
Law. This Omnibus Amendment shall be construed and interpreted in accordance with and be governed by the laws of the State of California without giving effect to any conflict of laws principles that would result in the application of the laws of
any state other than the State of California. 
 [Signature Pages Follow] 

									
		 		 	BAYHILL THERAPEUTICS, INC.
		 		 	a Delaware corporation
				
		 		 	By:	 	/s/ Mark W. Schwartz
		 		 		 	Name:	 	Mark W. Schwartz
		 		 		 	Title:	 	Chief Executive Officer and President
			
		 		 	MAJOR COMMON HOLDERS:
			
	LAWRENCE STEINMAN, MD	 		 	WILLIAM H. ROBINSON, MD, PHD
					
	By:	 	/s/ Lawrence Steinman, MD	 		 	By:	 	/s/ William H. Robinson, MD, PhD
			
	PAUL J. UTZ, MD	 		 	HIDEKI GARREN, MD, PHD
					
	By:	 	/s/ Paul J. Utz, MD	 		 	By:	 	/s/ Hideki Garrent, MD, PhD
			
	MARTIN H. GOLDSTEIN	 		 	
				
	By:	 	/s/ Martin H. Goldstein	 		 	

					
	PREFERRED STOCKHOLDERS:
	
	LATTERELL VENTURE PARTNERS, L.P.
		
	By:	 	Latterell Capital Management, L.L.C., its general partner
			
		 	By:	 	/s/ Patrick F. Latterell
		 		 	Patrick F. Latterell, Managing Member
	
	LATTERELL VENTURE PARTNERS II, L.P.
		
	By:	 	Latterell Capital Management II, L.L.C., its general partner
			
		 	By:	 	/s/ Patrick F. Latterell
		 		 	Patrick F. Latterell, Managing Member
	
	PREFERRED STOCKHOLDERS:
	
	U.S. Venture Partners VIII, L.P.
	USVP VIII Affiliates Fund, L.P.
	USVP Entrepreneur Partners VIII-A, L.P.
	USVP Entrepreneur Partners VIII-B, L.P.
	By Presidio Management Group VIII, L.L.C.
	The General Partner of Each
		
	By:	 	/s/ Michael P. Maher
		 	Michael P. Maher/Attorney-In-Fact

			
	PREFERRED STOCKHOLDERS:
	
	MORGENTHALER PARTNERS VII, L.P.
		
	By:	 	/s/ James Broderick, MD
	Name:	 	James Broderick, MD
	Title:	 	General Partner

			
	
	PREFERRED STOCKHOLDERS:
	
	VERTICAL FUND I, L.P.
		
	By:	 	The Vertical Group, L.P., General Partner
		
	By:	 	/s/ John Runnells
		 	John Runnells, General Partner
	
	VERTICAL FUND II, L.P.
		
	By:	 	The Vertical Group, L.P., General Partner
		
	By:	 	/s/ John Runnells
		 	John Runnells, General Partner

			
	PREFERRED STOCKHOLDERS:
	
	CMEA VENTURES LIFE SCIENCES 2000, L.P.
		
	By:	 	/s/ David J. Collier, MD
	Name:	 	David J. Collier, MD
	Title:	 	General Partner, CMEA Ventures LS Management 2000, L.P., the General Partner of CMEA Ventures Life Sciences 2000, L.P.
	
	CMEA VENTURES LIFE SCIENCES 2000, CIVIL LAW PARTNERSHIP
		
	By:	 	/s/ David J. Collier, MD
	Name:	 	David J. Collier, MD
	Title:	 	General Partner, CMEA Ventures LS Management 2000, L.P., the Managing Partner of CMEA Ventures Life Sciences 2000, Civil Law Partnership
	
	PREFERRED STOCKHOLDERS:
	
	THE MENDELSON FAMILY TRUST
		
	By:	 	/s/ Alan C. Mendelson
	Name:	 	Alan C. Mendelson
	
	LATHAM & WATKINS LLP
		
	By:	 	/s/ Alan C. Mendelson
	Name:	 	Alan C. Mendelson
	Title:	 	Senior Partner

					
	PREFERRED STOCKHOLDERS:
	
	LILLY VENTURES
	Eli Lilly and Company
		
	By:	 	/s/ Darren J. Carroll
	Name:	 	Darren J. Carroll
	Title:	 	Sr. Managing Director, Lilly Ventures

					
	
	PREFERRED STOCKHOLDERS:
	
	DE NOVO VENTURES II, L.P.
		
	By:	 	De Novo Management II, L.L.C., Its General Partner
			
		 	By:	 	/s/ Fred Dotzler by CM
		 		 	Fred Dotzler, Managing Director
	
	PREFERRED STOCKHOLDERS:
	
	A. M. PAPPAS LIFE SCIENCE VENTURES II, LP
		
	By:	 	AMP&A Management II, LLC, its General Partner
			
		 	By:	 	/s/ Ford S. Worthy
		 		 	Ford S. Worthy, Partner

					
	PREFERRED STOCKHOLDERS:
	
	MONTREUX EQUITY PARTNERS II SBIC, L.P.
		
	By:	 	Montreux Equity Management II, LLC,
		 	its General Partner
			
		 	By:	 	/s/ Daniel K. Turner
		 		 	Daniel K. Turner, III
		 		 	Managing Member
	
	MONTREUX EQUITY PARTNERS III SBIC, L.P.
		
	By:	 	Montreux Equity Management III, LLC,
		 	its General Partner
			
		 	By:	 	/s/ Daniel K. Turner
		 		 	Daniel K. Turner, III
		 		 	Managing Member

					
	
	PREFERRED STOCKHOLDERS:
	
	BOSTON LIFE SCIENCE VENTURE CORPORATION
		
	By:	 	/s/ Kenneth C. M. Lo
	Name:	 	Kenneth C. M. Lo
	Title:	 	Chairman

			
	PREFERRED STOCKHOLDERS:
	
	GRAND CATHAY VENTURE CAPITAL CO., LTD.
		
	By:	 	/s/ Edward Chang
	Name:	 	Edward Chang
	Title:	 	President
	
	PRUDENCE VENTURE INVESTMENT CORP.
		
	By:	 	/s/ Jessica Wu
	Name:	 	Jessica Wu
	Title:	 	President
	
	PREFERRED STOCKHOLDERS:
	
	PACLINK BIO VENTURE CAPITAL INVESTMENT CORP.
		
	By:	 	/s/ Allen Hsu
	Name:	 	Allen Hsu
	Title:	 	Chairman

			
	PREFERRED STOCKHOLDERS:
	
	PHARMABIO DEVELOPMENT, INC.
		
	By:	 	/s/ Tom Perkins
	Name:	 	Tom Perkins
	Title:	 	Senior Vice President

 BAYHILL THERAPEUTICS, INC. 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This Amended and Restated
Investor Rights Agreement (this “Agreement”) is made as of October 4, 2004, by and among Bayhill Therapeutics, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit A
hereto (each an “Investor”). 
 RECITALS 
 The Company and certain of the Investors have entered into a Series B Preferred Stock Purchase Agreement, of even date herewith (the
“Purchase Agreement”), pursuant to which the Company desires to sell to the Investors and the Investors desire to purchase from the Company shares of the Company’s Series B Preferred Stock. A condition to the
Investors’ obligations under the Purchase Agreement is that the Company and the Investors enter into this Agreement in order to provide the Investors with (i) certain rights to register shares of the Company’s Common Stock issuable
upon conversion of the Series B Preferred Stock held by the Investors, (ii) certain rights to receive or inspect information pertaining to the Company, and (iii) a right of first offer with respect to certain issuances by the Company
of its securities. The Company desires to induce the Investors to purchase shares of Series B Preferred Stock pursuant to the Purchase Agreement by agreeing to the terms and conditions set forth herein. 
 The Company had previously entered into that certain Investor Rights Agreement dated April 24, 2002, among the Company and certain Investors (the
“Prior Agreement”). The parties to the Prior Agreement want to amend and restate the Prior Agreement in its entirety, and to accept the rights and restrictions created in this Agreement in lieu of the rights and restrictions
contained in the Prior Agreement. Section 3.4 of the Prior Agreement vested the authority to amend the Prior Agreement in the Company and the holders of a majority of the Registrable Securities (as defined in the Prior Agreement) and provided
that any such amendment would be binding upon all parties to the Prior Agreement. The holders of a majority of the Registrable Securities (as defined in the Prior Agreement) are entering into this Agreement, making this Agreement binding upon all of
the parties to the Prior Agreement. 
 AGREEMENT 
 The parties agree as follows: 
  

	 	1.	Definitions; Registration Rights. 

 1.1 Definitions. For purposes of this Agreement: 
 (a) “Board” means the Board of
Directors of the Company, as the same shall be constituted from time to time. 
 (b) “Common Stock” means the
Common Stock of the Company. 

 (c) “Exempt Registration” means a registration statement relating to the
sale of securities by the Company pursuant to a stock option, stock purchase or similar benefit plan or an SEC Rule 145 transaction or any other registration statement that would not customarily provide for the sale of secondary equity shares
for cash. 
 (d) “Form S-3” means such form under the Securities Act as in effect on the date hereof or
any successor form under the Securities Act that is intended to be used as a short form for the registration of distributions of secondary shares. 
 (e) “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.11 of this Agreement. 
 (f) “Major Investor” means any Holder of at least 1,000,000 shares of Registrable Securities (as appropriately adjusted
for stock splits and the like). 
 (g) “person” means any individual, corporation, partnership, limited
liability company, trust, business, association or government or political subdivision thereof, governmental agency or other entity. 
 (h) “Qualified IPO” means a firm commitment, underwritten public offering registered under the Securities Act of 1933, as amended (the “Securities Act”) other than a registration relating solely to a
transaction under Rule 145 under the Securities Act (or any successor thereto) or to an employee benefit plan of the Company, at a public offering price equal to or exceeding $3.00 per share of Common Stock (as adjusted for any stock dividends,
combinations or splits with respect to such shares) and which results in aggregate cash proceeds to the Company in excess of $35,000,000 (net of underwriting discounts and commissions). 
 (i) “Preferred Stock” means the Series A Preferred Stock of the Company and the Series B Preferred Stock of the Company.

 (j) “register,” “registered,” and “registration” refer to a registration
effected by preparing and filing a registration statement or similar document in compliance with the Securities Act and the declaration or ordering of effectiveness of such registration statement or document. 
 (k) The term “Registrable Securities” means (i) the shares of Common Stock issuable or issued upon conversion of the
Preferred Stock, and (ii) any other shares of Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect
to, or in exchange for or in replacement of, the shares listed in clause (i) and this clause (ii); provided, however, that the foregoing definition shall exclude in all cases any Registrable Securities sold by a Holder in a
transaction in which its rights under this Agreement are not assigned. Notwithstanding the foregoing, securities shall only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a broker or dealer or
underwriter in a public distribution or a public securities transaction, or (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all transfer
restrictions, and restrictive legends with respect thereto, if any, are removed upon the consummation of such sale. 

 (l) The number of shares of “Registrable Securities then outstanding”
shall equal the number of shares of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are, Registrable Securities. 
 (m) “Registration Expenses” shall mean all expenses incurred by the Company in complying with Sections 1.3, 1.4, and 1.5
hereof, including, without limitation, all registration, qualification, listing and filing fees, printing expenses, accounting fees, escrow fees, fees and disbursements of counsel for the Company, fees and disbursements of one counsel for the
selling Holders selected by Holders selling a majority of the subject Registrable Securities with the approval of the Company, which approval shall not be unreasonably withheld, blue sky fees and expenses, and the expense of any special audits
incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company), but shall not include Selling Expenses or fees and disbursements of counsel for
the selling Holders in excess of $20,000. 
 (n) “SEC” means the Securities and Exchange Commission or any
other federal agency at the time administering the Securities Act. 
 (o) “Securities Act” means the
Securities Act of 1933, as amended (the “Securities Act”). 
 (p) “Selling Expenses” shall
mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the securities registered by the Holders and all fees and disbursements of counsel for any Holder, other than the fees and disbursements of one counsel for
all of the Holders registering securities in any given registration as provided in the definition of “Registration Expenses” above. 
 1.2 Request for Registration. 
 (a) Initiation. If the Company
shall receive at any time after the earlier of (i) October 4, 2008, or (ii) 180 days after the effective date of the first registration statement of the Company pertaining to its Common Stock (other than an Exempt Registration), a written
request from the Holders of at least twenty percent (20%) of the Registrable Securities then outstanding (the “Initiating Holders”) that the Company file a registration statement under the Securities Act covering the
registration of Registrable Securities with an anticipated aggregate offering price of at least seven million five hundred thousand dollars ($7,500,000.00), then the Company shall, within 10 days of the receipt thereof, give notice of such request
to all other Holders and shall, subject to the limitations of subsection 1.2(b), use its reasonable best efforts to effect as soon as practicable the registration under the Securities Act of all Registrable Securities which the Initiating
Holders request to be registered, together with any Registrable Securities of any Holder joining in such request as are specified in a notice given by any such Holder to the Company within 20 days after receipt of the Company’s notice.

 (b) Underwritten Offering. If the Initiating Holders intend to distribute
the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.2 and the Company shall include such information in the written notice
referred to in Section 1.2(a). The right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting. All Holders proposing to distribute their
Registrable Securities through such underwriting shall (together with the Company as provided in Section 1.5(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the
Company (which underwriter or underwriters shall be reasonably acceptable to a majority in interest of the Initiating Holders). Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Company in writing that
marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable
Securities that may be included in the underwriting shall be allocated among all participating Holders, including the Initiating Holders, in proportion (rounded to the nearest 100 shares) to the amount of Registrable Securities of the Company then
owned by each Holder; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. For
purposes of the preceding apportionment, for any participating Holder that is a partnership, limited liability company or corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and
family members of any such partners, members, retired partners or retired members and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder,” and any pro-rata reduction with
respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all Persons included in such “selling stockholder,” as defined in this sentence. 
 (c) Company Deferral. If the Company shall furnish to the Initiating Holders a certificate signed by the President or Chief
Executive Officer of the Company stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore essential to defer the
filing of such registration statement, the Company shall have the right to defer such filing for a period of not more than 120 days after receipt of the request of the Initiating Holders; provided, however, that the Company may not
utilize this right more than once in any 12-month period. 
 (d) Maximum Number of Registrations. The Company
shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2 after the Company has effected two (2) registrations pursuant to this Section 1.2 and such registrations have been
declared or ordered effective and the securities offered pursuant to such registrations have been sold. 
 (e) Lockout
Period. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2 during the period starting with the date 60 days prior to the Company’s good faith estimate of the
date of filing of, and ending on a date 180 days after the effective date of, a registration subject to Section 1.3 hereof; provided that if said registration statement is not yet effective, the Company shall be actively employing in
good faith all reasonable efforts to cause such registration statement to be filed and to become effective. 

 1.3 Company Registration. 
 (a) Initiation. If (but without any obligation to do so) the Company proposes to register (including for this purpose a
registration effected by the Company for stockholders other than the Holders) any of its stock in connection with the public offering of such securities solely for cash (other than an Exempt Registration), the Company shall, at such time, promptly
give each Holder notice of such registration. Upon the written request of each Holder given within 20 days after receipt by such Holder of the Company’s notice, the Company shall, subject to the provisions of Section 1.3(b), cause to be
registered all of the Registrable Securities that each such Holder has requested to be registered. 
 (b) Underwritten
Offering. In connection with any offering involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under Section 1.3(a) to include any of the Holders’ securities in such
underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters
determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of
securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities,
including Registrable Securities, which the underwriters determine in their sole discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata (to the nearest 100 shares) among the selling
stockholders according to the total amount of securities entitled to be included therein owned by each selling stockholder or in such other proportions as shall mutually be agreed to by such selling stockholders) but in no event shall the amount of
securities of the selling Holders included in the offering be reduced below twenty-five percent (25%) of the total amount of securities included in such offering, unless such offering is the initial public offering of the Company’s
securities, in which case, the selling stockholders may be excluded if the underwriters make the determination described above and no other stockholder’s securities are included. For purposes of the preceding apportionment, for any
participating Holder that is a partnership, limited liability company or corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any such partners, members, retired
partners or members and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder,” and any pro-rata reduction with respect to such “selling stockholder” shall be based
upon the aggregate amount of shares carrying registration rights owned by all Persons included in such “selling stockholder,” as defined in this sentence. 
 (c) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by
it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include Registrable Securities in such registration. 

 1.4 Form S-3 Registration. 
 (a) Initiation. If the Company shall receive from any Holder or Holders a written request or requests that the Company
effect a registration on Form S-3 with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will promptly give written notice of the proposed registration to all other Holders and as soon as
practicable, effect such registration of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such
request as are specified in a written request given within 20 days after receipt of such notice from the Company. 
 (b)
Limitations. Notwithstanding Section 1.4(a), the Company shall not be obligated to effect any such registration pursuant to this Section 1.4 (i) if Form S-3 is not available for such offering by the Holders;
(ii) if the Holders, together with the holders of any other securities of the Company entitled for inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public
(net of any underwriters’ discounts or commissions) of less than $1,000,000; (iii) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating either (A) that in the good faith judgment of
the Board, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to be effected at such time, or (B) that the underwriters have requested that the Company defer the filing of the Form S-3
following the effective date of a registration statement subject to Section 1.3, and, in either such event, the Company shall have the right to defer the filing of the Form S-3 for a period of not more than 120 days after receipt of the
request of the Holder or Holders under this Section 1.4; provided, however, that the Company shall not utilize this right more than once in any 12-month period; (iv) if the Company has, within the 12-month period preceding
the date of such request, already effected two (2) registrations on Form S-3 for the Holders pursuant to this Section 1.4. 
 (c) S-3’s not Demands. Registrations effected pursuant to this Section 1.4 shall not be counted as demands for registration or registrations effected pursuant to Section 1.2. 

(d) Underwritten Offerings. The substantive provisions of Section 1.2(b) shall apply to the registration if
it relates to an underwritten offering. 
 1.5 Obligations of the Company. Whenever required under this
Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, in the instances of a registration initiated
pursuant to Section 1.2 or 1.4, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to one hundred twenty (120) days or, if earlier, until the
distribution contemplated in the Registration Statement has been completed. 

 (b) Prepare and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act. 
 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request
in order to facilitate the disposition of such Registrable Securities. 
 (d) Use its reasonable best efforts to register and
qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection
therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement with the managing underwriter of such offering in usual and customary form and consistent
with the other provisions of this Agreement. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 
 (f) Promptly notify each Holder of Registrable Securities covered by the registration statement at any time when the Company becomes aware
of the happening of any event as a result of which the registration statement or the prospectus included in such registration statement or any supplement to the prospectus (as then in effect) contains any untrue statement of a material fact or omits
to state a material fact necessary to make the statements therein (in the case of the prospectus, in light of the circumstances under which they were made) not misleading or, if for any other reason it shall be necessary during such time period to
amend or supplement the registration statement or the prospectus in order to comply with the Securities Act, whereupon, in either case, each Holder shall immediately cease to use such registration statement or prospectus for any purpose and, as
promptly as practicable thereafter, the Company shall prepare and file with the SEC, and furnish without charge to the appropriate Holders and managing underwriters, if any, a supplement or amendment to such registration statement or prospectus
which will correct such statement or omission or effect such compliance and such copies thereof as the Holders and any underwriters may reasonably request. 
 (g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or over-the-counter market on which similar securities issued by the Company are then listed, if
applicable. 
 (h) Provide a transfer agent and registrar for such Registrable Securities and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such registration. 
 (i) Use its reasonable best
efforts to furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a 

 
registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through
underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance
as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a letter dated such date, from the independent
certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders
requesting registration of Registrable Securities (to the extent the then applicable standards of professional conduct permit said letter to be addressed to the Holders). 
 1.6 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action
pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. The Company shall have no obligation with respect to a specific registration requested pursuant to Section 1.2 or
Section 1.4 of this Agreement if, as a result of the application of the preceding sentence, the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or
exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in subsection 1.2(a) or subsection 1.4(b), whichever is applicable.

 1.7 Expenses of Registration. 
 (a) Demand and S-3 Registration. All Registration Expenses incurred in connection with registrations initiated
pursuant to Section 1.2 and 1.4 shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2 or 1.4 if the
registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses on a pro rata basis), unless the Holders of a
majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2 or one S-3 registration pursuant to Section 1.4, as applicable; provided further, however, that if
at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 1.2 and 1.4, as applicable. All Selling
Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of the registered securities included in such registration pro rata on the basis of the number of shares so registered. 
 (b) Company Registration. All Registration Expenses incurred in connection with registrations initiated pursuant to
Section 1.3 shall be borne by the Company. 

 1.8 Delay of Registration. No Holder shall have any right to obtain
or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 
 1.9 Indemnification. In the event any Registrable Securities are included in a registration statement under this
Section 1: 
 (a) Indemnification by the Company. To the extent permitted by law, the Company will
indemnify and hold harmless each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Securities Exchange Act of
1934, as amended (the “Exchange Act”), against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Company Violation”): (i) any untrue statement or
alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities
law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to each such Holder, underwriter or controlling person, as incurred, any legal or other expenses reasonably
incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 1.9(a) shall not apply to amounts paid
in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable to any Holder, underwriter or
controlling person for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Company Violation which occurs in reliance upon and in conformity with written information furnished expressly for use
in connection with such registration by any such Holder, underwriter or controlling person. 
 (b) Indemnification by
the Holders. To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the
Company within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or
liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect
thereto) arise out of or are based upon any of the following statements, omissions or violations (collectively, a “Holder Violation”): any (i) untrue statement of a material fact contained in such registration statement,
including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) omission to state therein a material fact required 

 
to be stated therein, or necessary to make the statements therein not misleading, or (iii) violation by the Company of the Securities Act, the Exchange
Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law, in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in
conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified
pursuant to this Section 1.9(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 1.9(b) shall not
apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, that in no event shall any
indemnity under this Section 1.9(b) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. 
 (c) Procedures. Promptly after receipt by an indemnified party under this Section 1.9 of notice of the commencement of
any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.9, deliver to the indemnifying party a written notice of the
commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel
mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate
counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests
between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its
ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.9, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Section 1.9. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment
or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. The indemnity agreements
contained in this Section 1.9 shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if such settlement is effected without the consent of the indemnifying party (which consent shall not be unreasonably
withheld). 
 (d) Contribution. If the indemnification provided for in this Section 1.9 is held by a court
of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall
contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the 

 
indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss,
liability, claim, damage or expense as well as any other relevant equitable considerations; provided, that in no event shall any contribution by a Holder under this Section 1.9(d) exceed the net proceeds from the offering received by
such Holder, except in the case of willful fraud by such Holder. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or
prevent such statement or omission. 
 (e) Underwriting Agreement. Notwithstanding the foregoing, to the extent
that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control. 
 (f) Survival. The obligations of the Company and Holders under this Section 1.9
shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 
 1.10 Reports Under Securities Exchange Act of 1934. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or
regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 
 (a) make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after the
effective date of the first registration statement filed by the Company for the offering of its securities to the general public so long as the Company remains subject to the periodic reporting requirements under Sections 13 or 15(d) of the
Exchange Act; 
 (b) take such action, including the voluntary registration of its Common Stock under Section 12 of the
Exchange Act, as is necessary to enable the Holders to use Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement filed by
the Company for the offering of its equity securities to the general public is declared effective; 
 (c) file with the SEC in
a timely manner all reports and other documents as may be required of the Company under the Securities Act and the Exchange Act; and 
 (d) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144, the Securities
Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), 

 
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and
(iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
 1.11 Assignment of Registration Rights. The rights to cause the Company to register securities granted Holders under
Sections 1.2, 1.3 and 1.4 may be assigned to a transferee or assignee in connection with any transfer or assignment of Registrable Securities by a Holder; provided that (a) such transfer may otherwise be effected in accordance with
applicable securities laws and restrictions on transfer agreed upon by the Holder and the Company (including those set forth in the Purchase Agreement), (b) written notice of such assignment is given to the Company, (c) such transferee or
assignee (i) is a wholly-owned subsidiary or constituent partner, retired partner, member, retired member or shareholder of such Holder, or (ii) is a spouse, ancestor or descendant or (iii) is a trust for the benefit of
such Holder or any spouse, ancestor or descendant of such Holder, or (iv) acquires from such Holder at least 100,000 Registrable Securities (as appropriately adjusted for stock splits and the like), (d) such transferee or assignee
agrees to be bound by all provisions of this Agreement, and (e) such transferee is not an actual or potential competitor of the Company, as determined in good faith by the Board. Notwithstanding the foregoing all assignees and transferees of a
Holder who acquire less than 100,000 Registrable Securities (as appropriately adjusted for stock splits and the like) from such Holder shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any
action under Section 1. 
 1.12 Limitations on Subsequent Registration Rights. From and after the
date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least a majority of the outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the
Company which would allow such holder or prospective holder (a) to include such securities in any registration filed under Section 1.2 hereof, unless under the terms of such agreement, such holder or prospective holder may include such
securities in any such registration only to the extent that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included or (b) to make a demand registration which could result in
such registration statement being declared effective prior to the earlier of either of the dates set forth in Section 1.2(a) or within 180 days after the effective date of any registration effected pursuant to Section 1.2. 
 1.13 Market-Standoff Agreement. 
 (a) Market-Standoff Period; Agreement. In connection with the initial public offering of the Company’s securities and
upon request of the Company or the underwriters managing such offering of the Company’s securities, each Holder hereby agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any
securities of the Company (other than any disposed of in the registration and those acquired by the Holder in the registration or thereafter in open market transactions) without the prior written consent of the Company or such underwriters, as the
case may be, for such period of time (not to exceed 180 days) from the effective date of such registration as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be requested by
the underwriters at the time of the Company’s initial public offering.  

 (b) Limitations. The obligations described in Section 1.13(a) shall
apply only if all executive officers and directors of the Company, all holders of at least one percent (1%) of the Company’s then outstanding securities (calculated on a fully diluted basis) enter into similar agreements. If the Company or
the underwriter of any public offering of the Company’s securities waive or terminate any standoff or lockup restrictions imposed on any holder of securities of the Company, then such waiver or termination shall be granted to all Holders
subject to standoff or lockup restrictions pro rata based on the number of shares of Common Stock beneficially held by such holder and the Holders. From and after the date of this Agreement, the Company shall use its best efforts to ensure that all
holders of capital stock of the Company agree to be bound by terms substantially similar to those set forth in this Section 1.13. 
 (c) Stop-Transfer Instructions. In order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to the securities of each Holder (and the securities of every
other person subject to the restrictions in Section 1.13(a)). 
 (d) Transferees Bound. Each Holder agrees
that, prior to the Company’s initial public offering, it will not transfer securities of the Company unless each transferee agrees in writing to be bound by all of the provisions of this Section 1.13. 
 (e) Legend. Each Holder agrees that a legend reading substantially as follows shall be placed on all certificates
representing all Registrable Securities of each Holder (and the shares or securities of every other person subject to the restriction contained in this Section 1.13): 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS AFTER THE EFFECTIVE DATE OF THE
ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S PRINCIPAL OFFICE. SUCH LOCK-UP
PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 
 1.14 Termination of Registration Rights. No Holder
shall be entitled to exercise any registration right provided for in this Section 1 after the earlier of (i) five (5) years following the consummation of a Qualified IPO, or (ii) such time as Rule 144 or another similar
exemption under the Securities Act is available for the sale of all of such Holder’s shares during a 90-day period without registration, without reference to Rule 144(k). 

	 	2.	Covenants of the Company. 

 2.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor (other than a Holder reasonably deemed by the Company to be a competitor of the Company): 
 (a) as soon as practicable, but in any event within 120 days after the end of each fiscal year of the Company, an income statement for
such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in reasonable detail, prepared in accordance
with generally accepted accounting principles (“GAAP”) consistently applied, and audited and certified by an independent public accounting firm of nationally recognized standing selected by the Company; 
 (b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters
of each fiscal year of the Company, a balance sheet of the Company as of the end of such quarterly period, and consolidated statements of income and cash flows of the Company for such quarterly period, prepared in accordance with GAAP consistently
applied, except such financial statements need not contain the notes required by GAAP; 
 (c) as soon as practicable, but in
any event within twenty (20) days of the end of each month, an unaudited income statement and a statement of cash flows and balance sheet for and as of the end of such month, in reasonable detail, and compared against the business plan for the
Company with respect to such month; 
 (d) as soon as practicable, but in any event thirty (30) days prior to the
beginning of each fiscal year, a budget and business plan for such fiscal year, prepared on a monthly basis, and, as soon as prepared, any other budgets or revised budgets prepared by the Company; 
 (e) a summary capitalization table including all share, option and warrant holders within twenty (20) days of the end of each
calendar quarter; and 
 (f) with respect to the financial statements called for in subsections (b) and (c) of this
Section 2.1, an instrument executed by the Chief Financial Officer or President of the Company and certifying that such financials were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the
exception of footnotes that may be required by GAAP) and fairly present the financial condition of the Company and its results of operation for the period specified, subject to year-end audit adjustment, provided that the foregoing shall not
restrict the right of the Company to change its accounting principles consistent with GAAP, if the Board determines that it is in the best interest of the Company to do so. 
 2.2 Inspection. The Company shall permit each Major Investor (except for a Holder reasonably deemed by the Company to
be a competitor of the Company), at such Holder’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all
at such reasonable times as may be requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.2 to provide access to any information which it reasonably considers to be a trade
secret or similar confidential information. 
 2.3 Right of First Offer. Subject to the terms and
conditions specified in this Section 2.3, the Company hereby grants to each Major Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). A Major Investor who chooses to exercise the
right of first offer may designate as purchasers under such right itself or its partners, members or affiliates in such proportions as it deems appropriate. 

 Each time the Company proposes to offer any shares of, or securities convertible into or
exercisable for any shares of, any class of its capital stock (“Shares”), the Company shall first make an offering of such Shares to each Major Investor in accordance with the following provisions: 
 (a) The Company shall deliver a notice (“Notice”) to the Major Investors stating (i) its bona fide intention to
offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares. 
 (b) Within 20 days after receipt of the Notice, the Major Investor may elect to purchase or obtain, at the price and on the terms
specified in the Notice, up to that portion of such Shares which equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable securities then held, by
such Major Investor bears to the total number of shares of Common Stock then outstanding (assuming full conversion and exercise of all outstanding convertible or exercisable securities). The Company shall promptly, in writing, inform each Major
Investor that purchases all the shares available to it (each, a “Fully-Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten-day period commencing after receipt of such information, each
Fully-Exercising Investor shall be entitled to elect to purchase or obtain that portion of the Shares for which Major Investors were entitled to subscribe but which were not subscribed for by the Major Investors that is equal to the proportion that
the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable securities then held, by such Fully-Exercising Investor bears to the total number of shares of Common Stock then
outstanding (assuming full conversion and exercise of all outstanding convertible or exercisable securities). 
 (c) The
Company may, during the 90-day period following the expiration of the period provided in subsection 2.3(b) hereof, offer the remaining unsubscribed portion of the Shares to any person or persons at a price not less than, and upon terms no more
favorable to the offeree than those specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within sixty (60) days of the execution thereof,
the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith. 
 (d) The term “Shares” shall not include (i) up to 5,949,052 shares of Common Stock issuable or issued to employees
or consultants rendering services to the Company or directors (in each case, if in a transaction with primarily non-financing purposes and primarily for the purpose of retaining their services for the Company) of this Company pursuant to a stock
option plan or restricted stock plan approved by the Board of Directors of the Company and the Compensation Committee thereof, if applicable; (ii) shares of Common Stock issued or issuable in connection with bona fide acquisitions, mergers,
technology licenses or purchases, corporate partnering agreements or similar transactions, the terms of which are approved by the Board of Directors of the Company; (iii) shares of Common Stock issued or 

 
issuable (A) in a public offering in connection with which all outstanding shares of Preferred Stock will be converted to Common Stock or (B) upon
exercise of warrants or rights granted to underwriters in connection with such a public offering; (iv) shares of Common Stock issued or issuable to financial institutions, landlords or lessors in connection with commercial credit agreements,
real estate transactions, equipment financings or similar transactions, the terms of which are approved by the Board of Directors of the Company; or (v) upon conversion of shares of Preferred Stock outstanding on the date of this Agreement or
upon exercise of warrants outstanding on the date of this Agreement. 
 2.4 Qualified Small Business Stock
Status. If the Company proposes to take an action or engage in a transaction that would reasonably be expected to result in the shares sold to the Investors pursuant to the Purchase Agreement no longer being “qualified small business
stock” within the meaning of Section 1202(c) of the Internal Revenue Code of 1986, as amended (the “Code”), the Company shall notify the Investors and consult in good faith to devise a mutually agreeable and reasonable
alternative course of action or transaction structure that would preserve such status. In addition, the Company shall submit to the Investors and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of
the Code and any related Treasury Regulations. In addition, within ten days after any Investor has delivered to the Company a written request therefor, the Company shall deliver to such Investor a written statement informing the Investor whether, in
the Company’s good-faith judgment after a reasonable investigation, such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. The Company’s
obligation to furnish a written statement pursuant to this Section 2.4 shall continue notwithstanding the fact that a class of the Company’s stock may be traded on an established securities market. 
 2.5 Board Approval of Compensation Plan and Employment Contracts. The Company’s compensation plan shall be subject to
the annual approval by a majority of the members of the Board of Directors. The Company shall not enter into any employment contract after the date of this Agreement without the consent of a majority of the members of the Board of Directors.

 2.6 Proprietary Information and Inventions; Consulting Agreements. The Company shall require all officers and
employees of the Company to enter into agreements in the Company’s standard form (which form shall be reasonably acceptable to the Company and the Investors) providing for the protection of proprietary information and assignment of inventions.
The Company shall require each consultant to the Company to execute a consulting agreement in the Company’s standard form (which form shall be reasonably acceptable to the Company and the Investors). 
 2.7 Stock Vesting. Unless otherwise approved by the Board of Directors, all common stock, stock options and other stock
equivalents granted or issued after the date of this Agreement to employees pursuant to the Company’s 2002 Stock Option Plan shall vest as follows: 20% at the end of the first 12 consecutive months of full-time employment, and monthly
thereafter at a rate of 1.66667% per month. 

 2.8 Compensation Committee. The Company shall, as soon as reasonably
practical following the date hereof and in no event later than sixty (60) days following the date hereof, form, and thereafter maintain, a compensation committee of the Board of Directors. The compensation committee shall consist of three
(3) members, at least one of whom shall be a director designated to the Board of Directors by De Novo Ventures, who shall initially be Fred Dotzler. 
 2.9 Termination of Covenants. 
 (a) The covenants set forth in Sections 2.1
through Section 2.8 shall terminate as to each Holder and be of no further force or effect immediately prior to the consummation of a Qualified IPO or a Change of Control (as defined below). 
 (b) The covenants set forth in Sections 2.1 and 2.2 shall terminate as to each Holder and be of no further force or effect when the
Company first becomes subject to the periodic reporting requirements of Sections 13 or 15(d) of the Exchange Act, if this occurs earlier than the events described in Section 2.5(a) above. 
 (c) A “Change of Control” occurs upon consummation of a transaction or series of related transactions resulting in
(i) a sale or transfer of all or substantially all of the Company’s assets; (ii) any person, “group” (as such term is used in Section 13(d)(3) of the Exchange Act) or entity becomes the “beneficial owner” (as
such term is defined in Rule 13d-3 promulgated under the Exchange Act) of more than fifty percent (50%) of the total voting power of the Company’s then outstanding securities; (iii) any merger with, acquisition of, consolidation
with or other similar transaction involving the Company, provided, however, that any merger with, acquisition of, consolidation with or other similar transaction involving the Company, in which the stockholders of the Company existing immediately
before such merger, acquisition or consolidation then own more than fifty percent (50%) of total voting power of the resulting entity’s then outstanding securities after giving effect to such merger, acquisition, consolidation or other
similar transaction, shall not constitute a Change of Control, and provided further that such a transaction effected solely to change the Company’s state of incorporation shall not constitute a Change of Control; or (iv) a liquidation,
dissolution or winding up of the Company. 
 (d) The Company shall reimburse the Investors for reasonable attorneys’ fees
and expenses incurred by the Investors for having one legal counsel advise the Investors collectively in connection with a proposed Change of Control that is approved by the Company’s Board. The Company’s obligation under this
Section 2.9(d) shall terminate upon the first consummation of a Change of Control and the reimbursement of such reasonable attorneys’ fees and expenses incurred by the Investors. 
  

	 	3.	Miscellaneous. 

 3.1
Entire Agreement. This Agreement constitutes the entire agreement among the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing among
any of the parties hereto are expressly canceled. 
 3.2 Recapitalizations, Etc.. The provisions of this
Agreement (including any calculation of share ownership) shall apply, to the full extent set forth herein with respect to the Registrable Securities and to the Common Stock, to any and all shares of capital stock of the 

 
Company or any capital stock, partnership or member units or any other security evidencing ownership interests in any successor or assign of the Company
(whether by merger, consolidation, sale of assets or otherwise) that may be issued in respect of, in exchange for, or in substitution of the Common Stock by reason of any stock dividend, split, combination, recapitalization, liquidation,
reclassification, merger, consolidation or otherwise. 
 3.3 Successors and Assigns. Except as otherwise
provided in this Agreement, and subject to the restriction on transfer set forth in the Purchase Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns
of the parties (including transferees of any of the Preferred Stock or any Common Stock issued upon conversion thereof). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 3.4 Amendments and Waivers. Any term of this Agreement may be amended or waived only with the written consent of the Company
and the holders of a majority of the Registrable Securities then outstanding. The Investors and their successors and assigns acknowledge that by operation of this Section 3.4, the holders of a majority of the then outstanding Registrable
Securities, when acting together with the Company, will have the right and power to diminish or eliminate any rights or increase any or all obligations under this Agreement.  
 3.5 Notices. Unless otherwise provided, any notice required or permitted by this Agreement shall be in writing and shall be
deemed sufficient upon delivery, when delivered personally or by overnight courier or sent by telegram or confirmed fax, or if mailed to a domestic address, 72 hours after being deposited in the U.S. mail, as certified or registered mail, with
postage prepaid, and addressed to the party to be notified at such party’s address or fax number as set forth below or on Exhibit A hereto or as subsequently modified by written notice. 
 3.6 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties
agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be excluded from this Agreement, (b) the
balance of the Agreement shall be interpreted as if such provision were so excluded and (c) the balance of the Agreement shall be enforceable in accordance with its terms. 
 3.7 Delays or Omissions; Remedies Cumulative. No delay or omission to exercise any right, power or remedy accruing to any
party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or
default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any
waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and
shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

 3.8 Attorney’s Fees. If any action at law or in equity (including
arbitration) is necessary to enforce or interpret the terms of any this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may
be entitled. 
 3.9 Governing Law. This Agreement and all acts and transactions pursuant hereto shall be
governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of laws. 
 3.10 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 3.11 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and
are not to be considered in construing or interpreting this Agreement. 
 3.12 Aggregation of Stock. All shares
of Company stock held or acquired by affiliated Persons (including former and current partners, former and current members and former and current stockholders) shall be aggregated together for the purpose of determining the availability of any
rights under this Agreement. 
 3.13 Confidentiality. Each Holder agrees that, except with the prior written
permission of the applicable party, it shall at all times keep confidential and not divulge, furnish or make accessible to anyone any confidential information, knowledge or data concerning or relating to the business or financial affairs of the
Company or any other party to which such Holder has been or shall become privy by reason of this Agreement (including Sections 2.1 and 2.2 hereof). The provisions of this Section 3.13 shall be in addition to, and not in substitution for, the
provisions of any separate nondisclosure agreement executed by the parties hereto with respect to the transactions contemplated hereby. Notwithstanding the foregoing, any Holder may disclose any such information which otherwise is generally
available to the public or which it is required to disclose to any governmental, administrative or regulatory authority, agency, department or body pursuant to any law, regulation, subpoena or judicial process, and any Holder may disclose such
proprietary or confidential information to any former, current or prospective partner, limited partner, general partner or management company of such Holder (or any employee or representative of any of the foregoing) (each of the foregoing persons,
a “Permitted Disclosee”) or legal counsel, accountants or representatives for such Holder or Permitted Disclosee, so long as such Permitted Disclosees are subject to equivalent confidentiality obligations. 
 3.14 Additional Parties. Persons who become “Purchasers” of the Company’s Series B Preferred Stock after the
effective date of this Agreement pursuant to and in accordance with the Purchase Agreement and who execute signature pages to this Agreement shall become parties hereto, and no consent or waiver of any other party hereto, other than the Company,
shall be required to add any such additional party. 

 3.15 Termination of Prior Agreement. The Prior Agreement is hereby
terminated in its entirety and restated herein. Such termination and restatement is effective upon execution of this Agreement by the Company and the holders of at least a majority of the Registrable Securities (as defined in the Prior Agreement),
pursuant to Section 3.4 thereof. Upon such execution, all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and terminated in their entirety and shall have no further force or effect.

 [SIGNATURE PAGE FOLLOWS] 

 The parties have executed this Amended and Restated Investor’s Rights Agreement as of the date first above written.

  

					
	BAYHILL THERAPEUTICS, INC.
		
	By:	 	/s/ Mark W. Schwartz
	Name:	 	Mark W. Schwartz
	Title:	 	President and CEO

					
	
	LATTERELL VENTURE PARTNERS, L.P.
		
	By:	 	Latterell Capital Management, L.L.C., its general partner
			
		 	By:	 	/s/ Patrick F. Latterell
		 		 	Patrick F. Latterell, Managing Member
	
	LATTERELL VENTURE PARTNERS II, L.P.
		
	By:	 	Latterell Capital Management II, L.L.C., its general partner
			
		 	By:	 	/s/ Patrick F. Latterell
		 		 	Patrick F. Latterell, Managing Member
	
	U.S. Venture Partners VIII, L.P.
	USVP VIII Affiliates Fund, L.P.
	USVP Entrepreneur Partners VIII-A, L.P.
	USVP Entrepreneur Partners VIII-B, L.P.
	By Presidio Management Group VIII, L.L.C.
	The General Partner of Each
		
	By:	 	/s/ Michael P. Maher
		 	Michael P. Maher/Attorney-In-Fact

			
	MORGENTHALER PARTNERS VII, L.P.
		
	By:	 	/s/ Robert C. Bellas, Jr.
	Name:	 	Robert C. Bellas, Jr.
	Title:	 	Managing Member

			
	
	VERTICAL FUND I, L.P.
		
	By:	 	The Vertical Group, L.P., General Partner
		
	By:	 	/s/ Stephen D. Baksa
		 	Stephen D. Baksa, General Partner
	
	VERTICAL FUND II, L.P.
		
	By:	 	The Vertical Group, L.P., General Partner
		
	By:	 	/s/ Stephen D. Baksa
		 	Stephen D. Baksa, General Partner

			
	
	CMEA VENTURES LIFE SCIENCES 2000, L.P.
		
	By:	 	/s/ David J. Collier, MD
	Name:	 	David J. Collier, MD
	Title:	 	General Partner
	
	CMEA VENTURES LIFE SCIENCES 2000, CIVIL LAW PARTNERSHIP
		
	By:	 	/s/ David J. Collier, MD
	Name:	 	David J. Collier, MD
	Title:	 	General Partner

					
	THE MENDELSON FAMILY TRUST
		
	By:	 	/s/ Alan C. Mendelson, Trustee
	Name:	 	Alan C. Mendelson
	
	LATHAM & WATKINS LLP
		
	By:	 	/s/ Alan C. Mendelson
	Name:	 	Alan C. Mendelson
	Title:	 	Senior Partner
	
	VP COMPANY INVESTMENTS 2004, LLC
		
	By:	 	/s/ Alan C. Mendelson
	Name:	 	Alan C. Mendelson
	Title:	 	Managing Member
	
	LILLY VENTURES
	Eli Lilly and Company
		
	By:	 	/s/ David Thompson
	Name:	 	David Thompson
	Title:	 	VP Corporate Strategy and Business Development
	
	DE NOVO VENTURES II, L.P.
		
	By:	 	De Novo Management II, L.L.C., Its General Partner
			
		 	By:	 	/s/ Fred Dotzler
		 		 	Fred Dotzler, Managing Director

					
	A. M. PAPPAS LIFE SCIENCE VENTURES II, LP
		
	By:	 	AMP&A Management II, LLC, its General Partner
			
		 	By:	 	/s/ Ford S. Worthy
		 		 	Ford S. Worthy, Partner

 The parties have executed this Amended and Restated Investor’s Rights Agreement as of January 7, 2005.

  

					
	MONTREUX EQUITY PARTNERS II SBIC, L.P.
		
	By:	 	Montreux Equity Management II, LLC,
		 	its General Partner
			
		 	By:	 	/s/ Daniel K. Turner, III
		 		 	Daniel K. Turner, III
		 		 	Managing Member
	
	MONTREUX EQUITY PARTNERS III SBIC, L.P.
		
	By:	 	Montreux Equity Management III, LLC,
		 	its General Partner
			
		 	By:	 	/s/ Daniel K. Turner, III
		 		 	Daniel K. Turner, III
		 		 	Managing Member

 The parties have executed this Amended and Restated Investor’s Rights Agreement as of February 3, 2005.

  

			
	BOSTON LIFE SCIENCE VENTURE CORPORATION
		
	By:	 	/s/ Kenneth C. M. Lo
	Name:	 	Kenneth C. M. Lo
	Title:	 	Chairman
	
	GRAND CATHAY VENTURE CAPITAL CO., LTD.
		
	By:	 	/s/ Edward Chang
	Name:	 	Edward Chang
	Title:	 	President
	
	PRUDENCE VENTURE INVESTMENT CORP.
		
	By:	 	/s/ Jessica Wu
	Name:	 	Jessica Wu
	Title:	 	President

 The parties have executed this Amended and Restated Investor’s Rights Agreement as of April 15, 2005.

  

			
	PACLINK BIO VENTURE CAPITAL INVESTMENT CORP.
		
	By:	 	/s/ Hsu Shan-Ko
	Name:	 	Hsu Shan-Ko
	Title:	 	Chairman
	
	QFINANCE INCORPORATED
		
	By:	 	/s/ John Russell
	Name:	 	John Russell
	Title:	 	President

 SCHEDULE A 
 INVESTORS 
  

					
			
	 Name/Address/Fax No.
	  	No. of Series A
Shares	 	No. of Series B
Shares
	 QFinance Incorporated
 4709 Creekstone Drive
 Durham, NC 27703
 Fax: (919) 998-7456
	  		 	1,000,000
			
	 PacLink Bio Venture Capital Investment Corp.
 14Fl., 2. Tun Hwa South Road, Sec.2,
 Taipei, Taiwan, R.O.C.
 Fax: 886-2-27552000
	  		 	1,404,494
			
	 Prudence Venture Investment Corp.
 3F., No. 245, Tun Hua S. Road, Sec. 1,
 Taipei 106, Taiwan
 Fax: 886-2-8773-3800
	  		 	468,164
			
	 Grand Cathay Venture Capital Co., LTD.
 3F., No. 245, Tun Hua S. Road, Sec. 1,
 Taipei 106, Taiwan
 Fax: 886-2-8773-3800
	  		 	655,430
			
	 Boston Life Science Venture Corporation
 5th Floor, No. 420, Fu-Hsin N. Road
 Taipei, Taiwan
	  		 	1,000,000
			
	 Contact address:
 2nd Floor, No. 97, Sung-Jen Road
 Taipei, Taiwan
 Fax: 866-2-8789-3567
	  		 	
			
	 Montreux Equity Partners II SBIC, L.P.
 3000 Sand Hill Road, Bldg. 1
 Suite 260
 Menlo Park, CA 94025
 Fax: (650) 234-1250
	  		 	1,404,495
			
	 Montreux Equity Partners III SBIC, L.P.
 3000 Sand Hill Road, Bldg. 1
 Suite 260
 Menlo Park, CA 94025
 Fax: (650) 234-1250
	  		 	1,404,494
			
	 A. M. Pappas Life Science Ventures II, LP
 7030 Kit Creek Road
 P.O. Box 110287
 Research Triangle Park, NC 27709
 Fax: (919) 998-3301
	  		 	2,340,823

					
			
	 Name/Address/Fax No.
	  	No. of Series A
Shares	  	No. of Series B
Shares
	 De Novo Ventures II, L.P.
 ATTN: Fred Dotzler
 1550 El Camino Real, Suite 150
 Menlo Park, CA 94025
 Fax: (650) 329-1315
	  		  	5,617,978
			
	 Lilly Ventures
 Eli Lilly and Company
 Lilly Corporate Center DC 1088
 Indianapolis, IN 46285
 Fax: (317) 651-3051
	  		  	4,681,648
			
	 U.S. Venture Partners VIII, L.P.
 ATTN: Michael P. Maher
 2735 Sand Hill Road
 Menlo Park, CA 94025
 Fax: 650-854-3018
	  	4,893,503	  	4,581,931
			
	 USVP VIII Affiliates Fund, L.P.
 ATTN: Michael P. Maher
 2735 Sand Hill Road
 Menlo Park, CA 94025
 Fax: 650-854-3018
	  	36,057	  	33,762
			
	 USVP Entrepreneur Partners VIII-A, L.P.
 ATTN: Michael P. Maher
 2735 Sand Hill Road
 Menlo Park, CA 94025
 Fax: 650-854-3018
	  	45,844	  	42,925
			
	 USVP Entrepreneur Partners VIII-B, L.P.
 ATTN: Michael P. Maher
 2735 Sand Hill Road
 Menlo Park, CA 94025
 Fax: 650-854-3018
	  	24,596	  	23,030
			
	 CMEA Ventures Life Sciences 2000, L.P.
 ATTN: David J. Collier, MD, General Partner
 One Embarcadero Center, Suite 3250
 San Francisco, CA 94111
 Fax: 415-352-1524
	  	2,814,057	  	2,208,052
			
	 CMEA Ventures Life Sciences 2000, Civil Law Partnership
 ATTN: David J. Collier, MD, General Partner
 One Embarcadero Center, Suite 3250
 San Francisco, CA 94111
 Fax: 415-352-1524
	  	185,943	  	132,772

					
			
	 Name/Address/Fax No.
	  	No. of Series A
Shares	  	No. of Series B
Shares
	 Vertical Fund I, L.P.
 ATTN: John Runnells, General Partner
 25 DeForest Avenue
 Summit, NJ 07901
 Fax: 908-273-9434
	  	796,400	  	696,957
			
	 Vertical Fund II, L.P.
 ATTN: John Runnells, General Partner
 25 DeForest Avenue
 Summit, NJ 07901
 Fax: 908-273-9434
	  	203,600	  	239,373
			
	 Latterell Venture Partners, L.P.
 ATTN: Patrick Latterell
 Four Embarcadero Center, Suite 2500
 San Francisco, CA 94111
 Fax: 415-399-9879
	  	500,000	  	468,165
			
	 Latterell Venture Partners II, L.P.
 ATTN: Patrick Latterell
 Four Embarcadero Center, Suite 2500
 San Francisco, CA 94111
 Fax: 415-399-9879
	  	2,000,000	  	1,872,659
			
	 VP Company Investments 2004, LLC
 ATTN: Alan Mendelson
 135 Commonwealth Drive
 Menlo Park, CA 94025
 Fax: 650-463-2600
	  	25,000	  	23,408
			
	 with a copy to
	  		  	
			
	 Latham & Watkins LLP
 National Administrative Office
 ATTN: Grant Johnson
 520 South Grand Avenue, Suite 200
 Los Angeles, CA 90071-2610
 Fax: 213-891-7123
	  		  	
			
	 The Mendelson Family Trust
 ATTN: Alan C. Mendelson
 76 De Bell Drive
 Atherton, CA 94027
 Fax: 650-853-1345
	  	25,000	  	23,408

					
			
	 Name/Address/Fax No.
	  	No. of Series A
Shares	  	No. of Series B
Shares
	 Morgenthaler Partners VII, L.P.
 ATTN: James Broderick, M.D., General Partner
 2710 Sand Hill Road, Suite 1000
 Menlo Park, CA 94025
 Fax: 650-388-7621
	  	3,000,000	  	2,808,989
		  	 	  	 
			
	 TOTAL
	  	14,550,000	  	33,132,957Warrant Agreement - GATX Ventures, Inc.

 Exhibit 4.3 
 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF
COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS
OF SECTION 7 OF THIS WARRANT. 
 TOLERION, INC. 
 WARRANT TO PURCHASE 45,000 SHARES 
 OF SERIES A PREFERRED STOCK 
 THIS CERTIFIES THAT, for value received, GATX VENTURES, INC. and its assignees are entitled to subscribe for and purchase 45,000 shares of the fully paid
and nonassessable Series A Preferred Stock (as adjusted pursuant to Section 4 hereof, the “Shares”) of TOLERION, INC., a Delaware corporation (the “Company”), at the price of $1.00 per share (such price
and such other price as shall result, from time to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions
hereinafter set forth. As used herein, (a) the term “Series Preferred” shall mean the Company’s presently authorized Series A Preferred Stock, and any stock into or for which such Series A Preferred Stock may hereafter be
converted or exchanged, and after the automatic conversion of the Series A Preferred Stock to Common Stock shall mean the Company’s Common Stock, (b) the term “Date of Grant” shall mean October 31, 2002, and
(c) the term “Other Warrants” shall mean any other warrants issued by the Company in connection with the transaction with respect to which this Warrant was issued, and any warrant issued upon transfer or partial exercise of or
in lieu of this Warrant. The term “Warrant” as used herein shall be deemed to include Other Warrants unless the context clearly requires otherwise. 
 1. Term. The purchase right represented by this Warrant is exercisable, in whole or in part, at any time and from time to time from the Date of Grant through the later of (i) ten (10) years after the
Date of Grant or (ii) five (5) years after the closing of the Company’s initial public offering of its Common Stock (“IPO”) effected pursuant to a Registration Statement on Form S-l (or its successor) filed under the
Securities Act of 1933, as amended (the “Act”). 
 2. Method of Exercise; Payment; Issuance of New Warrant. Subject
to Section 1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof, in whole or in part and from time to time, at the election of the holder hereof, by (a) the surrender of this Warrant (with
the notice of exercise substantially in the form attached hereto as Exhibit A-l duly completed and executed) at the principal office of the Company and by the payment to the Company, by certified or bank check, or by wire transfer to an
account designated by the Company (a “Wire Transfer”) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased; (b) if in connection with a registered public offering of
the Company’s 

 
securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the
principal office of the Company together with notice of arrangements reasonably satisfactory to the Company for payment to the Company either by certified or bank check or by Wire Transfer from the proceeds of the sale of shares to be sold by the
holder in such public offering of an amount equal to the then applicable Warrant Price per share multiplied by the number of Shares then being purchased; or (c) exercise of the “net issuance” right provided for in
Section 10.2 hereof. The person or persons in whose name(s) any certificate(s) representing shares of Series Preferred shall be issuable upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall
be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which this Warrant is exercised. In the
event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be delivered to the holder hereof as soon as possible and in any event within thirty (30) days after such exercise and,
unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be issued to the holder hereof as soon as
possible and in any event within such thirty-day period; provided that at such time as the Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, if requested by the holder of this Warrant,
the Company shall cause its transfer agent to deliver the certificate representing Shares issued upon exercise of this Warrant to a broker or other person (as directed by the holder exercising this Warrant) within the time period required to settle
any trade made by the holder after exercise of this Warrant. 
 3. Stock Fully Paid; Reservation of Shares. All Shares that may be
issued upon the exercise of the rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all preemptive rights and taxes, liens and charges with respect to the
issue thereof. During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights evidenced by this
Warrant, a sufficient number of shares of its Series Preferred to provide for the exercise of the rights represented by this Warrant and a sufficient number of shares of its Common Stock to provide for the conversion of the Series Preferred into
Common Stock. 
 4. Adjustment of Warrant Price and Number of Shares. The number and kind of securities purchasable upon the exercise
of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 
 (a) Reclassification or Merger. In case of any reclassification or change of securities of the class issuable upon exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to
par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another corporation (other than a merger with another corporation in which the Company is the acquiring and the surviving corporation
and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or
purchasing corporation, as the case may be, 

  

 -2- 

 
shall duly execute and deliver to the holder of this Warrant a new Warrant (in form and substance satisfactory to the holder of this Warrant), or the Company
shall make appropriate provision without the issuance of a new Warrant, so that the holder of this Warrant shall have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the
unexercised portion of this Warrant, and in lieu of the shares of Series Preferred theretofore issuable upon exercise of this Warrant, (i) the kind and amount of shares of stock, other securities, money and property receivable upon such
reclassification, change, merger or sale by a holder of the number of shares of Series Preferred then purchasable under this Warrant, or (ii) in the case of such a merger or sale in which the consideration paid consists all or in part of assets
other than securities of the successor or purchasing corporation, at the option of the holder of this Warrant, the securities of the successor or purchasing corporation having a value at the time of the transaction equivalent to the value of the
Series Preferred purchasable upon exercise of this Warrant at the time of the transaction. Any new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this
Section 4. The provisions of this Section 4(a) shall similarly apply to successive reclassifications, changes, mergers and sales. 
 (b) Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine its outstanding shares of Series Preferred, the Warrant Price
shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately increased and the number of Shares issuable hereunder shall
be proportionately decreased in the case of a combination. 
 (c) Stock Dividends and Other Distributions. If the Company at any time
while this Warrant is outstanding and unexpired shall (i) pay a dividend with respect to Series Preferred payable in Series Preferred, then the Warrant Price shall be adjusted, from and after the date of determination of shareholders entitled
to receive such dividend or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Series
Preferred outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Series Preferred outstanding immediately after such dividend or distribution; or (ii) make
any other distribution with respect to Series Preferred (except any distribution specifically provided for in Sections 4(a) and 4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant shall
receive upon exercise of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Series Preferred (or Common Stock issuable upon conversion thereof) as of the record date fixed for the
determination of the shareholders of the Company entitled to receive such dividend or distribution. 
 (d) Adjustment of Number of
Shares. Upon each adjustment in the Warrant Price, the number of Shares of Series Preferred purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately
prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 
  

 -3- 

 (e) Antidilution Rights. The other antidilution rights applicable to the Shares of Series
Preferred purchasable hereunder are set forth in the Company’s Certificate of Incorporation, as amended through the Date of Grant, a true and complete copy of which is attached hereto as Exhibit B (the “Charter”). Such
antidilution rights shall not be restated, amended, modified or waived in any manner that is adverse to the holder hereof without such holder’s prior written consent unless such restatement, amendment, modification or waiver affects the holder
in the same manner as it affects all other holders of Series Preferred. The Company shall promptly provide the holder hereof with any restatement, amendment, modification or waiver of the Charter promptly after the same has been made. 
 5. Notice of Adjustments. Whenever the Warrant Price or the number of Shares purchasable hereunder shall be adjusted pursuant to
Section 4 hereof, the Company provide written notice to the holder setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant
Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the
holder of this Warrant. In addition, whenever the conversion price or conversion ratio of the Series Preferred shall be adjusted, the Company shall provide written notice to the holder setting forth, in reasonable detail, the event requiring the
adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the conversion price or ratio of the Series Preferred after giving effect to such adjustment, and shall cause copies of such certificate to be mailed
(without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant. 
 6. Fractional
Shares. No fractional shares of Series Preferred will be issued in connection with any exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor based on the fair market value of the Series
Preferred on the date of exercise as reasonably determined in good faith by the Company’s Board of Directors. 
 7. Compliance with
Act; Disposition of Warrant or Shares of Series Preferred. 
 (a) Compliance with Act. The holder of this Warrant, by acceptance
hereof, agrees that this Warrant, and the shares of Series Preferred to be issued upon exercise hereof and any Common Stock issued upon conversion thereof are being acquired for investment and that such holder will not offer, sell or otherwise
dispose of this Warrant, or any shares of Series Preferred to be issued upon exercise hereof or any Common Stock issued upon conversion thereof except under circumstances which will not result in a violation of the Act or any applicable state
securities laws. Upon exercise of this Warrant, unless the Shares being acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm in writing
that the shares of Series Preferred so purchased (and any shares of Common Stock issued upon conversion thereof) are being acquired for investment and not with a view toward distribution or resale in violation of the Act and shall confirm such other
matters related thereto as may be reasonably requested by the Company. This Warrant and all shares of Series Preferred issued upon exercise of this Warrant and all shares of Common Stock issued upon conversion thereof (unless registered under the
Act and any applicable state securities laws) shall be stamped or imprinted with a legend in substantially the following form: 
  

 -4- 

 “THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT
REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY.”

 Said legend shall be removed by the Company, upon the request of a holder, at such time as the restrictions on the transfer of the
applicable security shall have terminated. In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of this Warrant as follows: 
 (1) The holder is aware of the Company’s business affairs and financial condition, and has acquired information about the Company sufficient to
reach an informed and knowledgeable decision to acquire this Warrant. The holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution”
thereof in violation of the Act. 
 (2) The holder understands that this Warrant has not been registered under the Act in reliance upon a
specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder’s investment intent as expressed herein. 
 (3) The holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Act and qualified under any applicable state securities laws, or unless exemptions from
registration and qualification are otherwise available. The holder is aware of the provisions of Rule 144, promulgated under the Act. 
 (4)
The holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Act. 
 (b)
Disposition of Warrant or Shares. With respect to any offer, sale or other disposition of this Warrant or any shares of Series Preferred acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or shares, the
holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence, if reasonably satisfactory to the Company, to the
effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or such shares of Series Preferred or
Common Stock and indicating whether or not under the Act certificates for this Warrant or such shares of Series Preferred to be sold or otherwise disposed of 

  

 -5- 

 
require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written
notice and reasonably satisfactory opinion or other evidence, the Company, as promptly as practicable but no later than fifteen (15) days after receipt of the written notice, shall notify such holder that such holder may sell or otherwise
dispose of this Warrant or such shares of Series Preferred or Common Stock, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 7(b) that the opinion of
counsel for the holder or other evidence is not reasonably satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such determination has been made. Notwithstanding the foregoing, this Warrant or such
shares of Series Preferred or Common Stock may, as to such federal laws, be offered, sold or otherwise disposed of in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been furnished with such information as the
Company may reasonably request to provide a reasonable assurance that the provisions of Rule 144 or 144A have been satisfied. Each certificate representing this Warrant or the shares of Series Preferred thus transferred (except a transfer pursuant
to Rule 144 or 144A) shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order to ensure
compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with such restrictions. 
 (c) Applicability of Restrictions. Neither any restrictions of any legend described in this Warrant nor the requirements of Section 7(b) above shall apply to any transfer of, or grant of a security interest in, this
Warrant (or the Series Preferred or Common Stock obtainable upon exercise hereof or thereof) or any part hereof (i) to a partner of the holder if the holder is a partnership or to a member of the holder if the holder is a limited liability
company, (ii) to a partnership of which the holder is a partner or to a limited liability company of which the holder is a member, or (iii) to any affiliate of the holder if the holder is a corporation; provided that in any
such transfer, if applicable, the transferee shall on the Company’s request agree in writing to be bound by the terms of this Warrant as if an original holder hereof. 
 8. Rights as Shareholders; Information. No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed the holder
of Series Preferred or any other securities of the Company which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the
rights of a shareholder of the Company or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or
otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. Notwithstanding the foregoing, the Company will transmit to the holder of this Warrant such
statements and notices sent to or made available generally by the Company to the holders of Series Preferred concurrently with the distribution thereof to such holders. 
 9. Registration Rights. The holder of this Warrant is hereby granted the rights, and assumes the obligations imposed, pursuant to Section 1 of that certain Amended and Restated Investor Rights Agreement
dated as of July 31, 2002, by and among the Company and the investors named therein (the “Rights Agreement”), as if the holder of this Warrant were a “Holder” as such 

  

 -6- 

 
term is defined in the Rights Agreement and as if the Series Preferred issuable upon exercise of this Warrant were shares of “Preferred Stock” as
such term is defined in the Rights Agreement; provided that: 
 (1) The holder of this Warrant may include its Registrable
Securities (as defined in the Rights Agreement) in any registration filed under Section 1.2 of the Rights Agreement only to the extent that the inclusion of its securities will not reduce the amount of Registrable Securities of the other
Holders to be included therein; 
 (2) The holder of this Warrant may demand registration pursuant to Section 1 of the Rights Agreement
only if such registration could not result in such registration statement being declared effective prior to the earlier of either the dates set forth in Section 1.2(a) of the Rights Agreement or within 120 days after the effective date of any
registration effected pursuant to Section 1.2 of the Rights Agreement; and 
 (3) The registration rights granted to the holder of this
Warrant are assignable by the holder as set forth in Section 1.11 of the Rights Agreement except that the requirement that an assignee receive from a transferring Holder at least 100,000 Registrable Securities shall not apply. With respect to
all of the securities covered by the registration rights granted to the holder of this Warrant, if there shall at any time be more than one holder entitled to such rights, all such holders shall have a single attorney-in-fact for purposes of
exercising any rights, receiving any notices or taking any action under Section 1 of the Rights Agreement. 
 10. Additional
Rights. 
 10.1 Acquisition Transactions. The Company shall provide the holder of this Warrant with at least twenty
(20) days’ written notice prior to closing thereof of the terms and conditions of any of the following transactions (to the extent the Company has notice thereof): (i) the sale, lease, exchange, conveyance or other disposition of all
or substantially all of the Company’s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other
reorganization) or series of related transactions, in which more than fifty percent (50%) of the voting power of the Company is disposed of. 
 10.2 Right to Convert Warrant into Stock: Net Issuance. 
 (a) Right to Convert. In addition to and without limiting
the rights of the holder under the terms of this Warrant, the holder shall have the right to convert this Warrant or any portion thereof (the “Conversion Right”) into shares of Series Preferred as provided in this
Section 10.2 at any time or from time to time during the term of this Warrant. Upon exercise of the Conversion Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”),
the Company shall deliver to the holder (without payment by the holder of any exercise price or any cash or other consideration) that number of shares of fully paid and nonassessable Series Preferred as is determined according to the following
formula: 
  

 -7- 

																			
	X =	 	   B - A  
	  		  		  		  		  		  		  		  	
		 	Y	  		  		  		  		  		  		  		  	

  

					
	Where:	  	X =	  	the number of shares of Series Preferred that shall be issued to holder
			
		  	Y =	  	the fair market value of one share of Series Preferred
			
		  	A =	  	the aggregate Warrant Price of the specified number of Converted Warrant Shares immediately prior to the exercise of the Conversion Right (i.e., the number of Converted Warrant Shares
multiplied by the Warrant Price)
			
		  	B =	  	the aggregate fair market value of the specified number of Converted Warrant Shares (i.e., the number of Converted Warrant Shares multiplied by the fair market value of one
Converted Warrant Share)

 No fractional shares shall be issuable upon exercise of the Conversion Right, and, if the number
of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the holder an amount in cash equal to the fair market value of the resulting fractional share on the Conversion Date
(as hereinafter defined). For purposes of Section 10 of this Warrant, shares issued pursuant to the Conversion Right shall be treated as if they were issued upon the exercise of this Warrant. 
 (b) Method of Exercise. The Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of the
Company together with a written statement (which may be in the form of Exhibit A-l or Exhibit A-2 hereto) specifying that the holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this
Warrant which are being surrendered (referred to in Section 10.2(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon receipt by the Company of this Warrant together with
the aforesaid written statement, or on such later date as is specified therein (the “Conversion Date”), and, at the election of the holder hereof, may be made contingent upon the closing of the sale of the Company’s Common
Stock to the public in a public offering pursuant to a Registration Statement under the Act (a “Public Offering”). Certificates for the shares issuable upon exercise of the Conversion Right and, if applicable, a new warrant
evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the holder within thirty (30) days following the Conversion Date. 
 (c) Determination of Fair Market Value. For purposes of this Section 10.2, “fair market value” of a share of Series
Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as of a particular date (the “Determination Date”) shall mean: 
 (i) If the Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company’s Registration Statement
relating to such Public 

  

 -8- 

 
Offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to
Public” specified in the final prospectus with respect to such offering. 
 (ii) If the Conversion Right is not exercised in connection
with and contingent upon a Public Offering, then as follows: 
 (A) If traded on a securities exchange, the fair market value of the Common
Stock shall be deemed to be the average of the closing prices of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such
fair market value of the Common Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred is then convertible; 
 (B) If traded on the Nasdaq Stock Market or other over-the-counter system, the fair market value of the Common Stock shall be deemed to be the average of the closing bid prices of the Common Stock over the five
trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the Common Stock multiplied by the number of shares of Common Stock into which each share of
Series Preferred is then convertible; and 
 (C) If there is no public market for the Common Stock, then fair market value shall be
determined by mutual agreement of the holder of this Warrant and the Company. 
 In making a determination under clauses (A) or (B) above, if on
the Determination Date, five trading days had not passed since the IPO, then the fair market value of the Common Stock shall be the average closing prices or closing bid prices, as applicable, for the shorter period beginning on and including the
date of the IPO and ending on the trading day prior to the Determination Date (or if such period includes only one trading day the closing price or closing bid price, as applicable, for such trading day). If closing prices or closing bid prices are
no longer reported by a securities exchange or other trading system, the closing price or closing bid price shall be that which is reported by such securities exchange or other trading system at 4:00 p.m. New York City time on the applicable trading
day. 
 10.3 Exercise Prior to Expiration. To the extent this Warrant is not previously exercised as to all of the Shares subject
hereto, and if the fair market value of one share of the Series Preferred is greater than the Warrant Price then in effect, this Warrant shall be deemed automatically exercised pursuant to Section 10.2 above (even if not surrendered)
immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Series Preferred upon such expiration shall be determined pursuant to Section 10.2(c). To the extent this Warrant or
any portion thereof is deemed automatically exercised pursuant to this Section 10.3, the Company agrees to promptly notify the holder hereof of the number of Shares, if any, the holder hereof is to receive by reason of such automatic
exercise. 
 11. Representations and Warranties. The Company represents and warrants to the holder of this Warrant as follows:

 (a) This Warrant has been duly authorized and executed by the Company and is a valid and binding obligation of the Company enforceable in
accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable
remedies. 
  

 -9- 

 (b) The Shares have been duly authorized and reserved for issuance by the Company and, when issued in
accordance with the terms hereof, will be validly issued, fully paid and nonassessable and free from preemptive rights. 
 (c) The rights,
preferences, privileges and restrictions granted to or imposed upon the Series Preferred and the holders thereof are as set forth in the Charter, and on the Date of Grant, each share of the Series Preferred represented by this Warrant is convertible
into one share of Common Stock. 
 (d) The shares of Common Stock issuable upon conversion of the Shares have been duly authorized and
reserved for issuance by the Company and, when issued in accordance with the terms of the Charter will be validly issued, fully paid and nonassessable. 
 (e) The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with the terms hereof will not be, inconsistent with the Company’s Charter or
by-laws, do not and will not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not and will not conflict with or contravene any provision of, or constitute a default under, any indenture,
mortgage, contract or other instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the registration or filing with or the taking of any action in respect of or by, any
Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings will be effected by the time required thereby. 
 (f) There are no actions, suits, audits, investigations or proceedings pending or, to the knowledge of the Company, threatened against the Company in any
court or before any governmental commission, board or authority which, if adversely determined, could have a material adverse effect on the ability of the Company to perform its obligations under this Warrant. 
 (g) The number of shares of Common Stock of the Company outstanding on the date hereof, on a fully diluted basis (assuming the conversion of all
outstanding convertible securities and the exercise of all outstanding options and warrants), does not exceed 19,550,000 shares. 
 12.
Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought. 
 13. Notices. Any notice, request, communication or other document required or permitted to be given or delivered to the holder hereof or the
Company shall be delivered, or shall be 

  

 -10- 

 
sent by certified or registered mail, postage prepaid, to each such holder at its address as shown on the books of the Company or to the Company at the
address indicated therefor on the signature page of this Warrant. 
 14. Binding Effect on Successors. This Warrant shall be binding
upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets, and all of the obligations of the Company relating to the Series Preferred issuable upon the exercise or
conversion of this Warrant shall survive the exercise, conversion and termination of this Warrant and all of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the holder hereof. 
 15. Lost Warrants or Stock Certificates. The Company covenants to the holder hereof that, upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such
mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate.

 16. Descriptive Headings. The descriptive headings of the various Sections of this Warrant are inserted for convenience only and do
not constitute a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted this Warrant. 
 17. Governing Law. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of California. 
 18. Survival of Representations, Warranties and Agreements. All representations and warranties of the Company and the holder hereof contained
herein shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration of rights hereunder. All agreements of the Company and the holder hereof contained herein shall survive
indefinitely until, by their respective terms, they are no longer operative. 
 19. Remedies. In case any one or more of the covenants
and agreements contained in this Warrant shall have been breached, the holders hereof (in the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and enforce their or its rights either by
suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant. 
 20. No Impairment of Rights. The Company will not, by amendment of its Charterer through any other means, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of
this Warrant against impairment. 
  

 -11- 

 21. Severability. The invalidity or unenforceability of any provision of this Warrant in any
jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and effect. 
 22. Recovery of Litigation Costs. If any legal action or other proceeding is brought for the enforcement of this Warrant, or because of an alleged
dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be entitled to recover reasonable attorneys’ fees and other costs incurred in that
action or proceeding, in addition to any other relief to which it or they may be entitled. 
 23. Entire Agreement; Modification. This
Warrant constitutes the entire agreement between the parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written, with
respect to such subject matter. 
 [Remainder of page intentionally left blank.] 
  

 -12- 

 The Company has caused this Warrant to be duly executed and delivered as of the Date of Grant specified
above. 
  

			
	TOLE RION, INC.
		
	By	 	 /s/ John P. Walker

	Title	 	Chairman – CEO
	Address:	 	 3430 West Bayshore Road
 Palo Alto, CA
94303

  

 -13- 

 EXHIBIT A-l 
 NOTICE OF EXERCISE 
 To: TOLERION. INC. (the “Company”) 
 1. The undersigned hereby: 
  

	 	 ̈	elects to purchase                      shares of [Series A Preferred
Stock] [Common Stock] of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full, or 

  

	 	 ̈	elects to exercise its net issuance rights pursuant to Section 10.2 of the attached Warrant with respect to
                     Shares of [Series A Preferred Stock] [Common Stock]. 

 2. Please issue a certificate or certificates representing
                     shares in the name of the undersigned or in such other name or names as are specified below: 
  

	
	  

	(Name)
	
	  

	
	  

	(Address)

 3. The undersigned represents that the aforesaid shares are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable
securities laws. 
  

	
	  

	(Signature)

  

			
	  
	 	
	(Date)	 	

 EXHIBIT A-2 
 NOTICE OF EXERCISE 
 To: TOLERION, INC. (the “Company”) 
 1. Contingent upon and effective immediately prior to the closing (the “Closing”) of the Company’s public offering contemplated by
the Registration Statement on Form S    , filed                     ,
        , the undersigned hereby: 
  ̈ elects to purchase                      shares of [Series A Preferred
Stock] [Common Stock] of the Company (or such lesser number of shares as may be sold on behalf of the undersigned at the Closing) pursuant to the terms of the attached Warrant, or 
  ̈ elects to exercise its net issuance rights
pursuant to Section 10.2 of the attached Warrant with respect to                      Shares of [Series A Preferred Stock] [Common
Stock]. 
 2. Please deliver to the custodian for the selling shareholders a stock certificate representing such
                     shares. 
 3.
The undersigned has instructed the custodian for the selling shareholders to deliver to the Company $                     or, if less, the net
proceeds due the undersigned from the sale of shares in the aforesaid public offering. If such net proceeds are less than the purchase price for such shares, the undersigned agrees to deliver the difference to the Company prior to the Closing.

  

	
	  

	(Signature)

  

			
	  
	 	
	(Date)	 	

 EXHIBIT B 
 CHARTER

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]